{
    "clinical_study": {
        "@rank": "72002", 
        "arm_group": [
            {
                "arm_group_label": "A", 
                "arm_group_type": "Experimental", 
                "description": "MPDL3280A + Zelboraf (vemurafenib)"
            }, 
            {
                "arm_group_label": "B", 
                "arm_group_type": "Experimental", 
                "description": "MPDL3280A + Zelboraf (vemurafenib)"
            }, 
            {
                "arm_group_label": "C", 
                "arm_group_type": "Experimental", 
                "description": "MPDL3280A + Zelboraf (vemurafenib)"
            }
        ], 
        "brief_summary": {
            "textblock": "This is an open-label, multicenter, Phase Ib, dose-escalation and cohort-expansi on study of\n      MPDL3280A in combination with Vemurafenib (Zelboraf\u00ae) in previously untreated patients with\n      BRAFV600-mutation positive metastatic melanoma."
        }, 
        "brief_title": "A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Vemurafinib (Zelboraf\u00ae) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Malignant Melanoma", 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologic or cytologic documentation of metastatic melanoma, with BRAFV600 mutation\n             as assessed by cobas\u00ae 4800 BRAF V600 Mutation Test. Origin of the primary tumor must\n             be known and may be of skin, mucosal, or acral locations but not of ocular origin.\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\n          -  Adequate hematologic and end organ function\n\n          -  Measurable disease per RECIST v1.1\n\n          -  For female patients of childbearing potential and male patients with partners of\n             childbearing potential, agreement to use an effective form of contraception  and to\n             continue its use for 6 months after discontinuation from the study\n\n        Exclusion Criteria:\n\n          -  Receipt of prior systemic anti-cancer therapy for unresectable, locally advanced or\n             metastatic melanoma\n\n          -  Receipt of prior MAPK inhibitor pathway agents, including MEK kinase inhibitor and\n             BRAF kinase inhibitor\n\n          -  Major surgical procedure within 28 days prior to Day 1 or anticipation of need for a\n             major surgical procedure during the course of the study\n\n          -  Radiotherapy </= 14 days prior to Day 1\n\n          -  Adverse events from prior anti-cancer therapy that have not resolved to Grade <= 1\n             except for alopecia\n\n          -  Current severe, uncontrolled systemic disease excluding cancer\n\n          -  Known clinically significant liver disease\n\n          -  Known primary central nervous system (CNS) malignancy or untreated or active CNS\n             metastases\n\n          -  Any ongoing malignancy other than melanoma\n\n          -  History or risk of autoimmune disease\n\n          -  History of idiopathic pulmonary fibrosis, risk of pulmonary toxicity, or evidence of\n             active pneumonitis on screening chest CT scan\n\n          -  History of HIV or hepatitis C infection\n\n          -  Active tuberculosis\n\n          -  Severe infections within 4 weeks prior to Cycle 1 Day 1 or Signs or symptoms of\n             infection within 2 weeks prior to Cycle 1 Day 1\n\n          -  Received oral or IV antibiotics within 2 weeks prior to Cycle 1 Day 1\n\n          -  Administration of a live, attenuated vaccine within 4 weeks before Cycle 1 Day 1 or\n             anticipation that such a live attenuated vaccine will be required during the study\n\n          -  History of clinically significant cardiac or pulmonary dysfunction\n\n          -  Treatment with systemic immunosuppressive medications within 4 weeks prior to Cycle 1\n             Day 1\n\n          -  Bisphosphonate therapy for symptomatic hypercalcemia\n\n          -  Pregnant or lactating women\n\n          -  Any vemurafenib-specific exclusion criteria"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "44", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 1, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01656642", 
            "org_study_id": "GP28384"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "A", 
                    "B", 
                    "C"
                ], 
                "description": "Intravenous repeating dose", 
                "intervention_name": "MPDL3280A", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "A", 
                    "B", 
                    "C"
                ], 
                "description": "Oral repeating dose", 
                "intervention_name": "Vemurafenib (Zelboraf\u00ae)", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "PD-L1", 
            "PD-1", 
            "PDL1", 
            "antiPD-L1", 
            "MPDL3280A", 
            "Melanoma", 
            "BRAF", 
            "MPDL320A"
        ], 
        "lastchanged_date": "June 2, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90025"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sarasota", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34232"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase Ib, Open-Label Study of The Safety and Pharmacology of MPDL3280A Administered in Combination With Vemurafenib (Zelboraf\u00ae) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: GP28384 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Genentech", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence of dose-limiting toxicities (DLTs)", 
                "safety_issue": "No", 
                "time_frame": "21 days following the first administration of MPDL3280A"
            }, 
            {
                "measure": "Nature of dose-limiting toxicities (DLTs)", 
                "safety_issue": "No", 
                "time_frame": "21 days following the first administration of MPDL3280A"
            }, 
            {
                "measure": "Incidence of adverse events and laboratory abnormalities graded per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.0", 
                "safety_issue": "No", 
                "time_frame": "approximately 12 months"
            }, 
            {
                "measure": "Nature of adverse events and laboratory abnormalities graded per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.0", 
                "safety_issue": "No", 
                "time_frame": "approximately 12 months"
            }, 
            {
                "measure": "Severity of adverse events and laboratory abnormalities graded per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.0", 
                "safety_issue": "No", 
                "time_frame": "approximately 12 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01656642"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence of anti-MPDL3280A antibodies", 
                "safety_issue": "No", 
                "time_frame": "approximately 12 months"
            }, 
            {
                "measure": "Change in vital signs, including electrocardiograms (ECGs)", 
                "safety_issue": "No", 
                "time_frame": "approximately 12 months"
            }, 
            {
                "measure": "Change in clinical laboratory results", 
                "safety_issue": "No", 
                "time_frame": "approximately 12 months"
            }, 
            {
                "measure": "Number of cycles and dose intensity of each component of the treatment regimen", 
                "safety_issue": "No", 
                "time_frame": "approximately 12 months"
            }
        ], 
        "source": "Genentech", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Genentech", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}